BRCA1 and ovarian cancer: While pathogenic variants of the BRCA1 and BRCA2 genes account for about one fourth of all breast and ovarian cancer families1, VUS are the result of a smaller fraction of all tests (2–20%)2,3 and cannot be used for identification of predisposed family members as long as their clinical relevance is clearly defined.